Lyell Immunopharma Inc
NASDAQ:LYEL
Lyell Immunopharma Inc
NASDAQ:LYEL
Price:
22.39
USD
-6.12%
Market Cap:
$521.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Lyell Immunopharma Inc
NASDAQ:LYEL
|
US |
|
N
|
N R Agarwal Industries Ltd
NSE:NRAIL
|
IN |
Balance Sheet
Balance Sheet Decomposition
Lyell Immunopharma Inc
Lyell Immunopharma Inc
Balance Sheet Decomposition is not available for
Lyell Immunopharma Inc
Lyell Immunopharma Inc
Balance Sheet
Lyell Immunopharma Inc
Lyell Immunopharma Inc
Currency: USD
| Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
97
|
140
|
294
|
124
|
146
|
106
|
60
|
|
| Cash Equivalents |
97
|
140
|
294
|
124
|
146
|
106
|
60
|
|
| Short-Term Investments |
339
|
472
|
321
|
517
|
401
|
265
|
187
|
|
| Other Current Assets |
4
|
5
|
12
|
11
|
8
|
9
|
14
|
|
| Total Current Assets |
440
|
618
|
626
|
651
|
555
|
380
|
261
|
|
| PP&E Net |
44
|
124
|
167
|
166
|
142
|
73
|
54
|
|
| PP&E Gross |
44
|
124
|
167
|
166
|
142
|
73
|
54
|
|
| Accumulated Depreciation |
1
|
5
|
15
|
32
|
52
|
71
|
74
|
|
| Long-Term Investments |
69
|
163
|
331
|
115
|
49
|
32
|
19
|
|
| Other Long-Term Assets |
3
|
3
|
4
|
5
|
5
|
6
|
6
|
|
| Total Assets |
556
N/A
|
908
+63%
|
1 127
+24%
|
938
-17%
|
750
-20%
|
491
-35%
|
340
-31%
|
|
| Liabilities | ||||||||
| Accounts Payable |
3
|
9
|
3
|
4
|
5
|
5
|
3
|
|
| Accrued Liabilities |
13
|
27
|
28
|
26
|
27
|
37
|
44
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
6
|
13
|
16
|
7
|
3
|
11
|
3
|
|
| Total Current Liabilities |
22
|
49
|
47
|
37
|
35
|
54
|
49
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
126
|
141
|
151
|
67
|
61
|
54
|
42
|
|
| Total Liabilities |
148
N/A
|
190
+29%
|
198
+4%
|
104
-47%
|
95
-9%
|
108
+14%
|
92
-15%
|
|
| Equity | ||||||||
| Common Stock |
519
|
1 011
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
130
|
334
|
584
|
768
|
1 002
|
1 345
|
1 620
|
|
| Additional Paid In Capital |
18
|
41
|
1 516
|
1 608
|
1 657
|
1 728
|
1 868
|
|
| Other Equity |
1
|
0
|
2
|
8
|
0
|
0
|
0
|
|
| Total Equity |
408
N/A
|
718
+76%
|
930
+29%
|
833
-10%
|
655
-21%
|
383
-42%
|
248
-35%
|
|
| Total Liabilities & Equity |
556
N/A
|
908
+63%
|
1 127
+24%
|
938
-17%
|
750
-20%
|
491
-35%
|
340
-31%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
12
|
12
|
12
|
12
|
13
|
15
|
21
|
|
Switch to:
Switch to:
See Also
Discover More
